[{"orgOrder":0,"company":"LLS PedAL Initiative","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase I","graph3":"LLS PedAL Initiative","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LLS PedAL Initiative \/ Kura Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LLS PedAL Initiative \/ Kura Oncology"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Kura Oncology","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Kura Oncology"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Leukemia & Lymphoma Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Leukemia & Lymphoma Society","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Leukemia & Lymphoma Society"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ EcoR1 Capital"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":1.49,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.49,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ AstraZeneca"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Ziftomenib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Ziftomenib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 05, 2025

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : KO-539 (ziftomenib)is a potent and selective, oral investigational menin inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 28, 2025

                          Lead Product(s) : Ziftomenib,Imatinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 08, 2025

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Kyowa Kirin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 05, 2025

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Kyowa Kirin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The collaboration aims to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with AML and other hematologic malignancies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $330.0 million

                          November 20, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Kyowa Kirin

                          Deal Size : $1,491.0 million

                          Deal Type : Collaboration

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 24, 2024

                          Lead Product(s) : Ziftomenib,Imatinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Ziftomenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastrointestinal Stromal Tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 23, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 08, 2024

                          Lead Product(s) : Ziftomenib,Imatinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          MD Anderson Cancer Center

                          Country arrow
                          PackExpo
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Ziftomenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 02, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Kura Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank